iRhythm Technologies
IRTC
Market cap $4.53B

141.91 USD

+5.14

3.76%

Updated Jul 30, 12:24 PM EDT

1 day

3.76%

5 days

5.59%

1 month

-7.83%

3 months

32.76%

6 months

31.72%

Year to date

58.67%

1 year

59.27%

5 years

10.95%

10 years

444.76%

About: iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Employees: 2,000

Healthcare Medical Devices

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

145% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 22

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]

22% more capital invested

Capital invested by funds: $3.09B [Q4 2024] → $3.77B (+$673M) [Q1 2025]

13% more funds holding

Funds holding: 224 [Q4 2024] → 252 (+28) [Q1 2025]

4.87% more ownership

Funds ownership: 109.66% [Q4 2024] → 114.53% (+4.87%) [Q1 2025]

2% less repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 81

40% less call options, than puts

Call options by funds: $14.4M | Put options by funds: $24M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$130

8%

downside

Avg. target

$147

4%

upside

High target

$167

18%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley Cecilia Furlong	4%upside $147	Overweight Maintained	15 Jul 2025
Citigroup Joanne Wuensch	18%upside $167	Buy Maintained	22 May 2025
Canaccord Genuity William Plovanic	2%downside $139	Buy Maintained	2 May 2025
Wells Fargo Nathan Treybeck	8%downside $130	Overweight Upgraded	2 May 2025
Baird Mike Polark	6%upside $150	Outperform Maintained	2 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about IRTC published over the past 30 days

IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into iRhythm Technologies, Inc. (NasdaqGS: IRTC). On May 30, 2023, the Company disclosed the receipt of a Warning Letter from the FDA regarding “non-conformities to regulations for medical devices, including medical device reporting requirements, relating to the Company's Zio AT.

IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC

Zacks Investment Research

Will iRhythm Technologies (IRTC) Report Negative Earnings Next Week? What You Should Know

iRhythm Technologies (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will iRhythm Technologies (IRTC) Report Negative Earnings Next Week? What You Should Know

iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025

SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025

IRHYTHM INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC

NEW YORK and NEW ORLEANS , July 11, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

IRHYTHM INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC

iRhythm Technologies Announces Board Member Retirements and New Director Appointments

SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors.

iRhythm Technologies Announces Board Member Retirements and New Director Appointments

IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into iRhythm Technologies, Inc. (NasdaqGS: IRTC). On May 30, 2023, the Company disclosed the receipt of a Warning Letter from the FDA regarding “non-conformities to regulations for medical devices, including medical device reporting requirements, relating to the Company's Zio AT.

IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC

New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease

New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease

New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease

Zacks Investment Research

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

Robbins LLP Informs iRhythm Technologies, Inc. (IRTC) Investors That the Class Action Beat the Motion to Dismiss

iRhythm misled investors by promoting Zio AT as a real-time monitor for high-risk patients, inflating stock prices that dropped when the truth emerged.

Robbins LLP Informs iRhythm Technologies, Inc. (IRTC) Investors That the Class Action Beat the Motion to Dismiss

iRhythm Technologies, Inc. (NASDAQ: IRTC) Investor Alert: Schubert Jonckheer & Kolbe LLP Investigating Possible Shareholder Claims for False Statements and Insider Trading

SAN FRANCISCO , June 17, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises iRhythm Technologies, Inc. investors that the firm is investigating potential legal claims relating to alleged false statements exaggerating the capabilities of iRhythm's wearable Zio AT heart event monitor. Current shareholders are encouraged to contact the firm.

iRhythm Technologies, Inc. (NASDAQ: IRTC) Investor Alert: Schubert Jonckheer & Kolbe LLP Investigating Possible Shareholder Claims for False Statements and Insider Trading

See News Rankings

Charts implemented using Lightweight Charts™